RxDoctor Payments Data

John Holder, MD

Interventional Pain Medicine · Hampstead, NCNPI 1093949463

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,101 of the $9,327 with a category attached, or 76.1%. 34 manufacturers reported payments, led by Boston Scientific at 29.7% of the total. Reporting peaked in 2022 at $2,765 and has fallen 69.4% since, to $846 in 2025.

$9,327in general payments, 2019–2025

Across 407 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Medtronic$2K
  • AbbVie$1K
  • Abbott$543
  • Amgen$384
  • Pfizer$323
  • plus $2K from 28 others

What the payments were for

  • Travel & lodging$2,22624%
  • Food & beverage$7,10176%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,327 in reported general payments places this provider in the 75th percentile of 45 interventional pain medicine providers in North Carolina.

See all interventional pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$152,790
Medicare patients
199
Services billed
4,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ButransBuprenorphine23$11,691
Oxycodone Hcl140$6,631
Buprenorphine Hcl68$6,228
Hysingla ErHydrocodone Bitartrate12$6,035
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl42$4,840
Buprenorphine29$4,043
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen132$3,457
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen120$2,153
Morphine Sulfate38$1,584
Pregabalin71$1,558
Fentanyl21$1,520
Duloxetine Hcl20$514
Morphine Sulfate ErMorphine Sulfate14$496
Hydromorphone Hcl18$445
Acetaminophen-CodeineAcetaminophen With Codeine17$404

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Hampstead

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →